Tomislav Dragovich, MD
Medical Oncology · Jacksonville, FLNPI 1518979715
Payments from drug & device makers
Across 77 payments — averaging $8500.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$248K
- E.r. Squibb & Sons, L.L.C.$182K
- Novocure Inc.$85K
- Kyowa Kirin Pharmaceutical Development, Inc$58K
- Eli Lilly$35K
- Pharmacyclics LLC, An Abbvie Company$29K
- plus $18K from 11 others
What the payments were for
- Speaking & faculty fees$6,80080%
- Travel & lodging$1,03112%
- Food & beverage$6438%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $248,416 |
| E.r. Squibb & Sons, L.L.C. | 5 | $181,675 |
| Novocure Inc. | 30 | $85,053 |
| Kyowa Kirin Pharmaceutical Development, Inc | 3 | $57,693 |
| Eli Lilly | 4 | $34,813 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $29,350 |
| Lilly USA, LLC | 4 | $7,831 |
| Mirati Therapeutics, Inc. | 2 | $4,655 |
| Halozyme Inc | 1 | $2,616 |
| Astrazeneca UK Limited | 2 | $1,965 |
| AstraZeneca | 1 | $103 |
| Roche Molecular Systems, Inc. | 1 | $91 |
| Beigene USA, Inc. | 1 | $86 |
| Intera Oncology, Inc | 1 | $67 |
| Eisai Inc. | 3 | $45 |
| Gilead(2 entities) | 2 | $34 |
| Pfizer | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMJUDO$103
How this compares
$654,521 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 18 | $65,961 |
| Prochlorperazine Maleate | 41 | $713 |
| Ondansetron Hcl | 37 | $261 |
| Dexamethasone | 11 | $248 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $146 |
| Pantoprazole Sodium | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Jacksonville
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
- Jonathan StrosbergTampa$9.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.